J&K Chief Secretary orders expedition in 2 hydro projects amid Pak's objections
Jammu and Kashmir Chief Secretary Atal Dulloo reviewed the sites of two major hydroelectric power projects - Rattle and Dul Hasti - in Kishtwar district and directed officials to expedite the construction and resolve operational bottlenecks.This comes as Pakistan has raised objections to Rattle and Dul Hasti projects on several occasions, citing concerns over water flow and compliance with the Indus Waters Treaty, which has been suspended by India in the wake of the April 22 Pahalgam terror attack.advertisementHowever, India maintains that the projects adhere to the treaty's guidelines and are crucial for the region's energy security and economic development.
The Chief Secretary conducted a detailed review of the 850 MW Rattle Hydroelectric Power Project and the 390 MW Dul Hasti hydroelectric power station.Jammu and Kashmir's Information and PR Department shared a glimpse of the visit on X. "Chief Secretary Atal Dulloo visited Rattle (850 MW) and Dul Hasti (390 MW) hydroelectric projects to review progress and operations. Emphasised on timely completion, quality standards and resolving bottlenecks. Held review meet with NHPC, CVPPL and district officials." At the Rattle project site in Drabshalla Block, Dulloo was briefed on the project's progress. He inspected critical infrastructure, including the power intake structure, coffer dam, underground powerhouse complex, and the tail-raised tunnel.advertisementThe Chief Secretary instructed project authorities to intensify efforts for timely completion while upholding quality standards and addressing key operational issues.At the Dul Hasti Hydroelectric Power Station, Dulloo assessed the plant's operational status and held interactions with on-site officials. He urged performance enhancement and resolution of pending concerns. A high-level meeting with representatives from NHPC, CVPPL and HOPs of all Kishtwar-based power projects followed the site inspections.In addition to the ongoing Rattle and Dul Hasti projects, two more hydropower plants are also under development on the river Chenab in Kishtwar district, positioning the region as a future powerhouse of clean energy.The Chief Secretary was accompanied by senior officials, including Principal Secretary of the Power Development Department H Rajesh Prasad and Managing Director of JKPDCL, Rahul Yadav.On May 14, the Chief Secretary confirmed that the Jammu and Kashmir government was actively assessing damage and fast-tracking relief measures in the border areas affected by recent shelling from Pakistani forces. Efforts to expand safety infrastructure, including the construction of additional bunkers, were also on.With ANI inputsMust Watch
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
42 minutes ago
- India Today
Elon Musk accuses Donald Trump of being named in Epstein files
23:42 The Indian delegation led by Shashi Tharoor met US Vice President J.D. Vance, securing a high-level meeting in Washington DC. The Pakistani delegation, led by Bilawal Bhutto Zardari, made claims about terrorism which were refuted by Tharoor.
Time of India
42 minutes ago
- Time of India
Chenab railway bridge: While India lays tracks in Kashmir, Pakistan cancels development projects
India builds while Pakistan borrows Live Events Engineering the future: The Chenab Bridge Built to last Vande Bharat: Trains of the future (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel Prime Minister Narendra Modi inaugurated the Chenab Bridge on Friday, marking a landmark moment for Indian infrastructure. Standing 359 metres above the Chenab River, the bridge is now the highest railway arch bridge in the world. It is expected to soon carry the high-speed Vande Bharat trains between Katra and Srinagar — a first for the Kashmir a video shared on Instagram, the Prime Minister gave a brief glimpse of the newly completed structure, calling it 'a step towards Naya Kashmir.' The inauguration is seen as a major step in India's long-term effort to transform connectivity and development in Jammu and Kashmir, a region historically shaped by conflict and geographic timing of the inauguration is significant. As India opens a strategic railway line through the tough Himalayan terrain, neighbouring Pakistan faces a very different reality — one marked by loan dependency, budget cuts, and a growing economic this year, Pakistan secured an $800 million loan from the Asian Development Bank . This followed a $1 billion tranche from the International Monetary Fund, part of a broader $7 billion bailout programme. India has publicly opposed both, arguing the funds could be diverted to support terrorism rather than their intended development the same time, Pakistan has raised its defence budget by 18% to ₹2.5 trillion, citing increased tensions with India. According to India Today, the Pakistani government plans to cancel 118 development projects worth ₹1,000 billion (PKR), given that its total development allocation for the current fiscal year is only ₹880 billion (PKR).Indian officials have also pointed to Pakistan's falling tax-to-GDP ratio — from 13% in 2018 to just 9.2% in 2023 — as an indicator of growing economic risk and weak revenue Chenab Bridge is a central part of the 272-kilometre-long Udhampur–Srinagar–Baramulla Railway Line (USBRL), a major infrastructure project estimated to cost ₹44,000 crore. The line includes 36 tunnels and 943 bridges and is designed to fully integrate Jammu and Kashmir with the Indian rail particular bridge lies between the Kauri and Bakkal sections of the USBRL. It connects remote areas and offers year-round rail access to the Kashmir Valley — a significant shift for both civilian travel and military also inaugurated the Anji Bridge , India's first cable-stayed railway bridge, from which the broader USBRL project was Chenab Bridge is not just symbolic — it is a feat of modern engineering. Built using 28,000 tonnes of steel and 66,000 cubic metres of concrete, the bridge is designed to endure the extremes of its mountain construction employed 'Tekla Technology', a digital design platform that allowed for high precision in both design and execution. The structure can withstand winds of up to 260 km/h, survive earthquakes up to magnitude 8, and is blast-resistant. Engineers estimate its operational lifespan to be around 120 addition to the bridge, Prime Minister Modi is also launching two Vande Bharat trains — currently India's fastest. These trains can reach speeds of up to 180 km/h and operate at an average of 130 km/h. By contrast, Pakistan's fastest train tops out at 105 km/ addition of these trains to the newly completed rail corridor underscores India's focus on high-speed, high-impact infrastructure — a vision that stands in sharp contrast to the financial and development setbacks being reported across the border.
Mint
an hour ago
- Mint
Despite trade war, US drug companies turn to China for key cancer treatments
The drug industry has spent months going along with the Trump administration's efforts to move manufacturing and investment into the U.S., and to disentangle the U.S. and Chinese economies. A long list of big pharmaceutical firms have committed tens of billions of dollars to factories and research facilities in the U.S. In the past few months, though, U.S. pharma companies have simultaneously supercharged their interest in China-based biotechs, announcing what are likely to be the biggest deals ever for the rights to experimental medicines invented by Chinese companies. So far, the Trump administration has been silent on the deals, which are worth around $25 billion in upfront and potential milestone payments and seem to fly in the face of White House policy. The deals could one day result in new options for sick patients, but they also pose a major risk to U.S. biotech firms. The domestic drug pipeline relies on capital from Big Pharma, and now those funds may be going to start-ups in Shanghai, rather than Cambridge, Mass. The recent deals follow a successful trial result last year by U.S. biotech Summit Therapeutics of a new immunotherapy cancer drug it licensed from Chinese firm Akeso. In the trial, the drug outperformed Merck's top-selling Keytruda, raising hopes that it could prove a major advancement in cancer treatment. Since then, Big Pharma companies have rushed to get their own drugs to compete with Summit's product. There was one deal in November, when Merck licensed an experimental drug from a Chinese drugmaker for around $500 million up front and another $2.7 billion in potential milestone payments. The biggest deals have come in just the past two weeks. In mid May, Pfizer said it would pay the Chinese biotech 3SBio $1.3 billion up front for its own competitor to the Summit drug, plus billions more in potential milestone payments. Pfizer is also making a $100 million equity investment in 3SBio. This past week, Bristol Myers Squibb said it would pay $3.5 billion over the next three years, plus billions more in potential milestone payments, for half the rights to a similar drug developed by a Chinese company called Biotheus, which German biotech BioNTech acquired a few months ago. These numbers would be big for any biotech licensing deal—the drugs remain far from approval. For Chinese-developed drugs, the payment sizes are unprecedented. 'These are pretty sophisticated companies allocating major capital here," says Craig Garthwaite, a professor and director of the program on healthcare at Northwestern University's Kellogg School of Management, of the latest deals. 'It's demonstrating the validity of the science." It's all happening while Big Pharma is doing its best to show the Trump administration that it can adapt to the president's agenda, as the industry seeks to head off threatened tariffs and drug price limits. Eli Lilly, Johnson & Johnson, Bristol Myers, and others have all announced tens of billions of dollars in planned U.S. investments in manufacturing and research facilities this year. The White House didn't respond to a request for comment. Washington has been increasingly anxious about the rapid development of China's biotech ecosystem. The Biosecure Act, which hasn't passed Congress, targets complex drug manufacturing in China, while a recent report commissioned by Congress called on the U.S. to take 'swift action" to compete with the Chinese biotech sector. Amid those stalled efforts, the pace of Chinese biotech innovation is picking up. Until recently, the U.S. drug industry had largely seen Chinese biotechs as a source for cheaper 'me too" assets, which echo but don't duplicate existing medicines. Now, with the latest cancer drug deals, Chinese companies are innovating a new class of drugs that every Big Pharma firm seems to think it needs to get in on. The Summit drug that got investors, analysts, and companies excited last year is known as a PD-1/VEGF bispecific antibody, which combines two proven cancer-fighting tools. Daina Graybosch, an analyst at Leerink Partners, says that companies in the U.S. and Europe have been experimenting with similar combinations, but never tested them in humans. That's because early-stage human tests are cheaper and easier to run in China than the U.S. All but the largest U.S. biotechs generally develop just one or two experimental medicines at a time, while Chinese biotechs of a similar size 'could have a dozen" different drugs in trials, according to Cantor Fitzgerald analyst Li Watsek. The combination cancer drugs ultimately weren't exciting enough for the U.S. biotechs to prioritize. But Chinese companies moved forward with different variations. When Summit and its Chinese partner got promising results on an antibody that combined PD-1 and VEGF, there were multiple other Chinese biotechs with their own PD-1/VEGF combinations ready to of this is great news for the U.S. biotech sector, which has been battered in recent years by declining share prices, cash shortfalls, and other challenges. Over the past 12 months, the SPDR S&P Biotech exchange-traded fund is down 11.5%, versus a gain of 11.7% for the S&P 500. Watsek says that part of the problem for investors is that it's hard to know what Chinese biotechs are actually working on. 'Right now it's a little bit of a black box, because a lot of these Chinese companies, they may have assets, but it's impossible to track," she says. 'There could be a dozen molecules that are in development that you may not have even heard of." Over the long term, the worries get potentially more complex. 'At some point, it's going to get terminal velocity, and we're going to have a very dangerous competitor next to us," says Joseph Grogan, a senior policy official during the first Trump administration who is now a nonresident senior scholar at the USC Schaeffer Institute. 'If the Chinese establish the flywheel of the ecosystem that we built—of private-sector companies, research and development, government support, and strong but prudent regulatory foundation—then we're cooked." Write to Josh Nathan-Kazis at
